CJC-1295 No DAC vs Ipamorelin: Synergy or Overlap?

The reason these compounds are not in competition is straightforward: they bind different receptors.

CJC-1295 No DAC (also called Modified GRF 1-29, or Mod GRF 1-29) is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor (GHRHR) on pituitary somatotrophs. GHRHR activation stimulates GH synthesis and secretion through the Gs/cAMP/PKA signalling pathway — the same mechanism as endogenous GHRH, but with greater stability and a longer half-life than the native peptide (~30 minutes vs the 2–5 minutes of native GHRH).

Ipamorelin is a GHS-R1a agonist — it binds the ghrelin receptor on pituitary somatotrophs and hypothalamic neurons. GHS-R1a activation stimulates GH release through a calcium-dependent pathway (Gq/IP3/calcium signalling) that is mechanistically distinct from the cAMP pathway activated by GHRHR.

Two different receptors. Two different intracellular signalling cascades. Both converging on somatotroph GH secretion — but via independent routes.

The synergistic relationship between GHRH-class compounds and GHS-R1a agonists has been documented since the 1990s. The mechanism operates at two levels:

At the pituitary: Simultaneous activation of GHRHR (via CJC-1295 No DAC) and GHS-R1a (via ipamorelin) in the same somatotroph cells triggers both the cAMP/PKA and the calcium signalling cascades simultaneously. The co-activation of two distinct intracellular pathways amplifies GH secretion beyond what either pathway achieves alone. Published studies document GH pulse amplitudes from dual-receptor stimulation that substantially exceed the additive effects of each compound independently.

At the hypothalamus: Ipamorelin activates GHS-R1a in hypothalamic neurons that suppress somatostatin release. CJC-1295 No DAC simultaneously stimulates GHRH-sensitive neurons. The result is increased GHRH stimulation of the pituitary combined with reduced somatostatin inhibition — both effects reinforcing the same GH-releasing outcome.

This is the mechanistic basis for combination protocols: both compounds working through independent pathways that converge on the same endpoint.

While synergistic when combined, CJC-1295 No DAC and ipamorelin have different properties that matter for research protocol timing and design:

The half-life difference has specific relevance for research sampling design: CJC-1295 No DAC (~30 min) is substantially shorter-lived than ipamorelin (~2 hours). Protocols sampling downstream markers at 2–4 hours post-administration will observe CJC-1295 No DAC's contribution primarily through its acute stimulation of the first GH pulse, while ipamorelin's contribution extends further into the sampling window.

A common source of confusion in the research literature: CJC-1295 No DAC (Mod GRF 1-29) is a fundamentally different compound from CJC-1295 with DAC (Drug Affinity Complex). The DAC modification covalently binds the peptide to albumin in plasma, extending its half-life to approximately 6–8 days. This produces a continuous, non-pulsatile GH elevation rather than a physiological pulse.

Research protocols designed to study acute GH pulse dynamics use CJC-1295 No DAC specifically for this reason — the shorter half-life preserves the pulsatile release pattern the research is examining. Research examining sustained GH elevation instead uses the DAC form.

When studying CJC-1295 No DAC and ipamorelin in combination: the standard approach in published research is to administer both compounds at the same time or in close sequence, taking advantage of the coincident receptor engagement window. The shorter half-life of CJC-1295 No DAC means its GHRHR stimulation peaks early; ipamorelin's GHS-R1a engagement is more sustained through the protocol window.

When studying them independently: each compound provides clean data on its receptor class. CJC-1295 No DAC isolates GHRHR pharmacology. Ipamorelin isolates GHS-R1a pharmacology without the HPA co-stimulation of less selective GHRPs such as GHRP-6. See Ipamorelin vs GHRP-6 → for the selectivity comparison.

Both compounds require reconstitution with bacteriostatic water. See How to Reconstitute a Research Peptide → for full protocol. For half-life data relevant to sampling design, see Peptide Biological Half-Lives →.